SOPHiA GENETICS (NASDAQ:SOPH) and Decision Diagnostics (OTCMKTS:DECN) Financial Comparison

Decision Diagnostics (OTCMKTS:DECN) and SOPHiA GENETICS (NASDAQ:SOPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Risk and Volatility

Decision Diagnostics has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Valuation & Earnings

This table compares Decision Diagnostics and SOPHiA GENETICS”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A
SOPHiA GENETICS	$65.17 million	4.20	-$62.49 million	($0.44)	-9.20

Decision Diagnostics has higher earnings, but lower revenue than SOPHiA GENETICS.

Institutional & Insider Ownership

31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Decision Diagnostics and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decision Diagnostics	N/A	N/A	N/A
SOPHiA GENETICS	-40.99%	-30.69%	-17.39%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Decision Diagnostics and SOPHiA GENETICS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decision Diagnostics	0	0	0	0	0.00
SOPHiA GENETICS	1	0	1	0	2.00

SOPHiA GENETICS has a consensus target price of $8.00, indicating a potential upside of 97.53%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than Decision Diagnostics.

Summary

SOPHiA GENETICS beats Decision Diagnostics on 7 of the 10 factors compared between the two stocks.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.